<doc>
  <docmeta id="113s752is">
    <bill congress="113" type="s" number="752" version="is"/>
    <revision size="5347" annotations="0" id="4" commit-time="2013-05-15T23:10:42Z" status="complete" committer="mbohmer" doc="113s752is/4.xml">
      <description description="Markup copied from completed documents">Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-Senate" public-private="public">
  <metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dublinCore>
      <dc:title>113 S752 IS: Cody Miller Initiative for Safer Prescriptions Act</dc:title>
      <dc:publisher>U.S. Senate</dc:publisher>
      <dc:date>2013-04-17</dc:date>
      <dc:format>text/xml</dc:format>
      <dc:language>EN</dc:language>
      <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    </dublinCore>
  </metadata>
  <form>
    <distribution-code display="yes">II</distribution-code>
    <congress>113th CONGRESS</congress>
    <session>1st Session</session>
    <legis-num>S. 752</legis-num>
    <current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
    <action>
      <action-date date="20130417">April 17, 2013</action-date>
      <action-desc>
        <sponsor name-id="S331">Mrs. Gillibrand</sponsor>introduced the following bill; which was read twice and referred to the<committee-name committee-id="SSHR00">Committee on Health, Education, Labor,
			 and Pensions</committee-name>
      </action-desc>
    </action>
    <legis-type>A BILL</legis-type>
    <official-title>To require the Secretary of Health and Human Services to
		  promulgate regulations regarding the authorship, content, format, and
		  dissemination of Patient Medication Information to ensure patients receive
		  consistent and high-quality information about their prescription medications
		  and are aware of the potential risks and benefits of prescription
		  medications.</official-title>
  </form>
  <legis-body>
    <section id="S1" section-type="section-one">
      <enum>1.</enum>
      <header>Short
			 title</header>
      <text display-inline="no-display-inline">This Act may be cited as
			 the<quote>
          <short-title>Cody Miller Initiative for Safer
			 Prescriptions Act</short-title>
        </quote>.</text>
    </section>
    <section id="idAA61AF00658E4330A743C9B4335C8370">
      <enum>2.</enum>
      <header>Patient
			 medication information for prescription drugs</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:V">Chapter V of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref>(<external-xref legal-doc="usc" parsable-cite="usc/21/351">
            <cato:entity-ref entity-type="uscode" value="usc/21/351/etseq">21 U.S.C. 351 et seq.</cato:entity-ref>
          </external-xref>)</cato:entity>is amended by inserting after<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505E">section 505E</cato:entity-ref>the following:</text>
      <quoted-block display-inline="no-display-inline" id="id31426cebabac48888f10f11d4f8a1e09" style="OLC">
        <section id="IDb1fbe0398ab84aa29a82a09e5082a74f">
          <enum>505F.</enum>
          <header>Patient
				medication information for prescription drugs</header>
          <subsection id="id7e439920f90b40c593de3da38d6c73d6">
            <enum>(a)</enum>
            <header>In
				general</header>
            <text>Not later than 2 years after the date of enactment of
				this section, the<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>shall issue regulations regarding the authorship,
				content, format, and dissemination requirements for patient medication
				information (referred to in this section as<term>PMI</term>) for drugs subject
				to<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:b/p:1">section 503(b)(1)</cato:entity-ref>.</text>
          </subsection>
          <subsection id="id256a68871ee4467bbfc257d7f8c40b7f">
            <enum>(b)</enum>
            <header>Content</header>
            <text>The
				regulations promulgated under<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505F/ss:a" proposed="true">subsection (a)</cato:entity-ref>shall require that the PMI with
				respect to a drug—</text>
            <paragraph id="ida7c52660a06c4e04ad104c545fa869d9">
              <enum>(1)</enum>
              <text>be scientifically
				accurate and based on the professional labeling approved by the<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1200">Secretary</cato:entity-ref>and
				authoritative, peer-reviewed literature; and</text>
            </paragraph>
            <paragraph id="id913e8bde9004406ba6a7e38b95a5ca6b">
              <enum>(2)</enum>
              <text>includes
				nontechnical, understandable, plain language that is not promotional in tone or
				content, and contains at least—</text>
              <subparagraph id="id13c29c29e94f46f6a18c6c4d4cf5dc24">
                <enum>(A)</enum>
                <text>the established
				name of drug, including the established name of such drug as a listed drug (as
				described in<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:2/sp:A">section 505(j)(2)(A)</cato:entity-ref>) and as a drug that is the subject of an
				approved abbreviated new drug application under<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j">section 505(j)</cato:entity-ref>or of an
				approved license for a biological product submitted under<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351/ss:k">section 351(k) of the
				Public Health Service Act</cato:entity-ref>, if applicable;</text>
              </subparagraph>
              <subparagraph id="id870e0c61844b4ce2ad327278fbbb16ca">
                <enum>(B)</enum>
                <text>drug uses and
				clinical benefits;</text>
              </subparagraph>
              <subparagraph id="ida719636afcc84896a07104c9745cf7c0">
                <enum>(C)</enum>
                <text>general
				directions for proper use;</text>
              </subparagraph>
              <subparagraph id="id0ea55ebffcd9422d88f67b5bbb797a1e">
                <enum>(D)</enum>
                <text>contraindications,
				common side effects, and most serious risks of the drug, especially with
				respect to certain groups such as children, pregnant women, and the
				elderly;</text>
              </subparagraph>
              <subparagraph id="id763b843781db4c75b9c1c7bf83c71dca">
                <enum>(E)</enum>
                <text>measures patients
				may be able to take, if any, to reduce the side effects and risks of the
				drug;</text>
              </subparagraph>
              <subparagraph id="id14ea989028f142f993a98c7449bb7c66">
                <enum>(F)</enum>
                <text>when a patient
				should contact his or her health care professional;</text>
              </subparagraph>
              <subparagraph id="id0cb57c33017b495185c9aa3d7425ac1e">
                <enum>(G)</enum>
                <text>instructions not
				to share medications, and, if any exist, key storage requirements, and
				recommendations relating to proper disposal of any unused portion of the drug;
				and</text>
              </subparagraph>
              <subparagraph id="idaad819a411754306a157ffbc219547a2">
                <enum>(H)</enum>
                <text>known clinically
				important interactions with other drugs and substances.</text>
              </subparagraph>
            </paragraph>
          </subsection>
          <subsection id="id49a3687d19ab4e7ba4a19002e5c5bfa5">
            <enum>(c)</enum>
            <header>Timeliness,
				consistency, and accuracy</header>
            <text>The regulations promulgated under<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505F/ss:a" proposed="true">subsection (a)</cato:entity-ref>shall include standards related to—</text>
            <paragraph id="ida54e7c20ddea4c238c4c8d3eaa5b36c4">
              <enum>(1)</enum>
              <text>performing timely
				updates of drug information as new drugs and new information becomes
				available;</text>
            </paragraph>
            <paragraph id="idfd09a5b112c14fa6aa908051e1efe9fc">
              <enum>(2)</enum>
              <text>ensuring that
				common information is applied consistently and simultaneously across similar
				drug products and for drugs within classes of medications in order to avoid
				patient confusion and harm; and</text>
            </paragraph>
            <paragraph id="idb865f79f8f2e43aabac0eeddae80de0a">
              <enum>(3)</enum>
              <text>developing a
				process, including consumer testing, to assess the quality and effectiveness of
				PMI in ensuring that PMI promotes patient understanding and safe and effective
				medication use.</text>
            </paragraph>
          </subsection>
          <subsection id="idb6f0e5db64ca4858a6871ef2be01863a">
            <enum>(d)</enum>
            <header>Electronic
				repository</header>
            <text>The regulations promulgated under<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505F/ss:a" proposed="true">subsection (a)</cato:entity-ref>shall
				provide for the development of a publicly accessible electronic repository for
				all PMI documents and content to facilitate the availability of
				PMI.</text>
          </subsection>
        </section>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
    </section>
    <section id="id1285d1bb0fb94349874b2ae38571fdf9">
      <enum>3.</enum>
      <header>Publication on
			 internet website</header>
      <text display-inline="no-display-inline">The<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary
			 of Health and Human Services</cato:entity-ref>shall publish on the Internet website of the<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food
			 and Drug Administration</cato:entity-ref>a link to the Daily Med website
			 (http://dailymed.nlm.nih.gov/dailymed) (or any successor website).</text>
    </section>
  </legis-body>
</bill>
</doc>